866-997-4948(US-Canada Toll Free)

Epithelial Ovarian Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Ovarian Cancer

No. of Pages : 244 Pages

Epithelial Ovarian Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Epithelial Ovarian Cancer - Pipeline Review, H2 2014, provides an overview of the Epithelial Ovarian Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Epithelial Ovarian Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Epithelial Ovarian Cancer - Overview 9
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 10
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 11
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 15
Epithelial Ovarian Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Epithelial Ovarian Cancer - Products under Development by Companies 19
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 21
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 22
Johnson & Johnson 22
Boehringer Ingelheim GmbH 23
F. Hoffmann-La Roche Ltd. 24
Amgen Inc. 25
Oxford BioMedica plc 26
Millennium Pharmaceuticals, Inc. 27
ImmunoGen, Inc. 28
Bayer AG 29
Incyte Corporation 30
Active Biotech AB 31
Topotarget A/S 32
NeoStem, Inc. 33
Pharmacyclics, Inc. 34
Prima BioMed Ltd. 35
Synta Pharmaceuticals Corp. 36
Oasmia Pharmaceutical AB 37
Glycotope GmbH 38
BioNumerik Pharmaceuticals, Inc. 39
CerRx, Inc. 40
Immunotope, Inc. 41
Pharma Mar, S.A. 42
VentiRx Pharmaceuticals, Inc. 43
Clovis Oncology, Inc. 44
Recepta Biopharma S.A. 45
EGEN, Inc. 46
Sanofi Pasteur SA 47
AbbVie Inc. 48
Sotio a.s. 49
Epithelial Ovarian Cancer - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 56
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 65
trebananib - Drug Profile 65
paclitaxel - Drug Profile 69
cositecan - Drug Profile 71
bevacizumab - Drug Profile 73
trabectedin - Drug Profile 78
rucaparib phosphate - Drug Profile 81
sorafenib tosylate - Drug Profile 84
alisertib - Drug Profile 88
abiraterone acetate - Drug Profile 91
tasquinimod - Drug Profile 94
PankoMab-GEX - Drug Profile 96
elesclomol - Drug Profile 97
belinostat - Drug Profile 99
TroVax - Drug Profile 102
nintedanib - Drug Profile 105
CVac - Drug Profile 108
VTX-2337 - Drug Profile 111
RebmAb-100 - Drug Profile 113
EGEN-001 - Drug Profile 115
INCB-24360 - Drug Profile 117
DCVAC/OvCa - Drug Profile 119
Cancer Stem Cell Therapy - Drug Profile 121
fenretinide - Drug Profile 122
CDX-1401 - Drug Profile 124
ganetespib - Drug Profile 126
fosbretabulin tromethamine - Drug Profile 130
BNC-105P - Drug Profile 134
Cell Therapy Targeting Survivin and hTERT for Epithelial Ovarian Cancer - Drug Profile 136
Enadenotucirev - Drug Profile 137
OPB-111001 - Drug Profile 139
Cell Therapy Targeting NY-ESO-1 and LAGE-1 for Cancer - Drug Profile 140
Procure - Drug Profile 142
birinapant + conatumumab - Drug Profile 143
abexinostat hydrochloride - Drug Profile 145
nintedanib - Drug Profile 147
IMT-1012 - Drug Profile 150
vCP-2292 - Drug Profile 151
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 153
Cell Therapy for Oncology - Drug Profile 154
IMGN-853 - Drug Profile 155
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Drug Profile 156
anetumab ravtansine - Drug Profile 157
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 159
Small Molecule for Oncology - Drug Profile 160
ABT-898 - Drug Profile 162
NERX-505X - Drug Profile 163
NERX-313E - Drug Profile 164
Epithelial Ovarian Cancer - Recent Pipeline Updates 165
Epithelial Ovarian Cancer - Dormant Projects 233
Epithelial Ovarian Cancer - Discontinued Products 234
Epithelial Ovarian Cancer - Product Development Milestones 235
Featured News & Press Releases 235
Appendix 240
Methodology 240
Coverage 240
Secondary Research 240
Primary Research 240
Expert Panel Validation 240
Contact Us 241
Disclaimer 241

List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H2 2014 12
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Development by Companies, H2 2014 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2014 25
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 26
Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 27
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H2 2014 28
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H2 2014 29
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 30
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H2 2014 31
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H2 2014 32
Epithelial Ovarian Cancer - Pipeline by Incyte Corporation, H2 2014 33
Epithelial Ovarian Cancer - Pipeline by Active Biotech AB, H2 2014 34
Epithelial Ovarian Cancer - Pipeline by Topotarget A/S, H2 2014 35
Epithelial Ovarian Cancer - Pipeline by NeoStem, Inc., H2 2014 36
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 37
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H2 2014 38
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 39
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 40
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2014 41
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2014 42
Epithelial Ovarian Cancer - Pipeline by CerRx, Inc., H2 2014 43
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H2 2014 44
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H2 2014 45
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 46
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 47
Epithelial Ovarian Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 48
Epithelial Ovarian Cancer - Pipeline by EGEN, Inc., H2 2014 49
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H2 2014 50
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H2 2014 51
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H2 2014 52
Assessment by Monotherapy Products, H2 2014 53
Assessment by Combination Products, H2 2014 54
Number of Products by Stage and Target, H2 2014 57
Number of Products by Stage and Mechanism of Action, H2 2014 61
Number of Products by Stage and Route of Administration, H2 2014 64
Number of Products by Stage and Molecule Type, H2 2014 67
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2014 168
Epithelial Ovarian Cancer - Dormant Projects, H2 2014 236
Epithelial Ovarian Cancer - Discontinued Products, H2 2014 237

List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H2 2014 12
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Products, H2 2014 21
Assessment by Monotherapy Products, H2 2014 53
Number of Products by Top 10 Target, H2 2014 55
Number of Products by Stage and Top 10 Target, H2 2014 56
Number of Products by Top 10 Mechanism of Action, H2 2014 59
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 60
Number of Products by Top 10 Route of Administration, H2 2014 63
Number of Products by Stage and Top 10 Route of Administration, H2 2014 64
Number of Products by Top 10 Molecule Type, H2 2014 65
Number of Products by Stage and Top 10 Molecule Type, H2 2014 66

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *